breast%20cancer
BREAST CANCER
Breast cancer is the presence of malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the breast. The lump or mass is usually painless, hard & irregular but it can also be tender, soft, rounded or painful.
Other signs & symptoms include breast pain or nipple pain, nipple discharge, nipple retraction and presence of breast skin changes (eg peau d' orange, nipple excoriation, scaling, inflammation, skin tethering, ulceration, abscess).
Drug Information

Indication: Advanced stage ovarian cancer of epithelial origin.

Indication: Advanced ovarian carcinoma of epithelial origin.

Indication: Alone or in combination for palliative treatment of malignant tumours, particularly of breast, colon or rectum...

Indication: Locally advanced or metastatic non-small cell lung cancer (NSCLC) & pancreatic adenocarcinoma; fluorouraci...

Indication: Hodgkin's disease (stages 3 & 4), advanced testicular carcinoma. Palliative treatment of lymphocytic &...

Indication: Acute leukemia. In combination w/ other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphom...

Indication: Breast, gastric, ovarian & small cell lung cancer; non-Hodgkin's lymphoma; advanced/metastatic soft tissue...

Indication: Treatment & prevention of osteoporosis in postmenopausal women. Reduction in risk of invasive breast cance...

Indication: Adjuvant treatment of postmenopausal women w/ estrogen receptor +ve early breast cancer who have received 2-3 ...

Indication: Postmenopausal women w/ estrogen receptor +ve & HER2 -ve if not previously treated w/ endocrine therapy, l...

2  /  8
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 12 Jun 2019

Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving 2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.